Clinical trial
Celecoxib in Treating Patients With Precancerous Lesions of the Mouth
NCT00014404 · Memorial Sloan Kettering Cancer Center, Other · Completed
Key facts
| NCT number | NCT00014404 |
|---|---|
| Title | Celecoxib in Treating Patients With Precancerous Lesions of the Mouth |
| Official title | Phase II Double-Blind, Placebo Controlled, Randomized Study Of Celecoxib, A Selective COX-2 Inhibitor, In Oral Premalignant Lesions |
| Lead sponsor | Memorial Sloan Kettering Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Head and Neck Cancer |
| Intervention type | Drug |
| Interventions | celecoxib |
| Start date | Oct 1, 2000 |
| Primary completion | Jan 1, 2006 |
| First posted | Jan 7, 2004 |
| Last update posted | Jan 16, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: